Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure—A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)

Hamaguchi, Sanae; Kinugawa, Shintaro; Tsuchihashi-Makaya, Miyuki; Goto, Daisuke; Yamada, Satoshi; Yokoshiki, Hisashi; Tsutsui, Hiroyuki

doi:10.1016/j.jjcc.2013.03.009

Cited by 63 publications

(65 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Coronary artery disease, as the etiology of HF, is relatively lower in Japan than in Western countries 29, 30. Use of angiotensin‐converting enzyme inhibitors and β‐blockers was comparably lower.…”

Section: Discussionmentioning

confidence: 97%

“…Use of angiotensin‐converting enzyme inhibitors and β‐blockers was comparably lower. Angiotensin receptor blockers were more commonly used in Japan, while angiotensin‐converting enzyme inhibitors were more frequently used than angiotensin receptor blockers in Western countries 30. Although the mean length of hospital stay was considerably longer than in Western countries,29, 30 in‐hospital mortality was comparable, and mortality rate after discharge was lower in Japan than in Western countries 29…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Clinical Significance of Get With the Guidelines–Heart Failure Risk Score in Patients With Chronic Heart Failure After Hospitalization

Suzuki

Yoshihisa

Sato

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundThe Get With the Guidelines–Heart Failure (GWTG‐HF) risk score was developed using American Heart Association GWTG‐HF program data and predicts in‐hospital mortality in patients with acute heart failure (HF). We aimed to clarify the prognostic impacts of the GWTG‐HF risk score in patients with HF after discharge.Methods and ResultsWe examined the GWTG‐HF score in 1452 patients with HF, who were admitted to our hospital and discharged after treatment, by calculating 7 predetermined variables. We divided all subjects into 3 groups according to the GWTG‐HF risk score (low, moderate, and high score groups). The plasma B‐type natriuretic peptide level significantly increased with increasing GWTG‐HF risk score severity (median values of B‐type natriuretic peptide: 167.0 in low, 260.7 in moderate, and 418.2 pg/mL in high score groups). We followed up all subjects after discharge, and there were 347 (23.9%) all‐cause deaths and 407 (28.0%) cardiac events in follow‐up periods. A Kaplan‐Meier survival curve demonstrated that event rates of all‐cause death and cardiovascular events, including worsening HF and cardiac death, significantly increased with increasing GWTG‐HF risk score severity in all subjects, and also in 749 patients with HF with preserved ejection fraction (ejection fraction ≥50%) and 703 patients with HF with reduced ejection fraction (ejection fraction <50%) patients. The multivariable Cox proportional hazard regression analysis demonstrated that the GWTG‐HF risk score was one of the significant predictors of all‐cause mortality and cardiac events (all‐cause mortality: hazard ratio, 1.537, 95% confidence interval, 1.172–2.023; cardiac events: hazard ratio, 1.584, 95% confidence interval, 1.344–1.860, per 10‐point increase of GWTG‐HF score).ConclusionsThe GWTG‐HF risk score is a useful multivariable score model for several years after hospitalization in patients with HF in a Japanese population.

show abstract

Section: Discussionmentioning

confidence: 97%

Section: Discussionmentioning

confidence: 99%

Clinical Significance of Get With the Guidelines–Heart Failure Risk Score in Patients With Chronic Heart Failure After Hospitalization

Suzuki

Yoshihisa

Sato

et al. 2018

JAHA

View full text Add to dashboard Cite

show abstract

“…We also compared these data with those from Japanese HF registries, including the acute decompensated HF syndromes (ATTEND) registry, 11 the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD), 12 and the Heart Institute of Japan-Department of Cardiology (HIJC)-HF Registry. 13 …”

Section: Patients' Characteristicsmentioning

confidence: 99%

Clinical Characteristics of Adult Patients With Congenital Heart Disease Hospitalized for Acute Heart Failure

Negishi

Ohuchi

Miyazaki

et al. 2018

Circ J

View full text Add to dashboard Cite

Background: Heart failure (HF) is an important complication in adults with congenital heart disease (CHD), but because only a few studies have focused on acute HF hospitalization in adults with CHD, we study aimed to define the clinical characteristics of such patients and examine the differences in acute HF between adults with CHD and acquired heart disease. Methods and Results:We retrospectively evaluated 50 adults with CHD admitted for treatment of acute HF and compared their data with those from Japanese HF registries. Patient mean age was 37±15 years and 58% were male. In total, 86% of the patients had complex forms of CHD and 62% had undergone corrective surgery, including the Fontan procedure; 66% of patients showed right heart hemodynamic abnormality. In-hospital mortality was 4%, which was comparable to the Japanese HF registries. Survival rate was 93% at 1 year and 75% at 3 years, which was similarly poor to the rates of HF secondary to acquired heart disease. Conclusions:We clarified the clinical characteristics of adults with CHD requiring HF hospitalization. Young adults with complex CHD were hospitalized for management of acute right HF. Short-term and mid-term outcomes were similarly poor compared with acute HF secondary to acquired heart disease.

show abstract

“…However, to date, no randomized clinical trials have evaluated the chronic effects of loop diuretics on the long-term outcomes of such patients 38) . Previous subanalyses of randomized clinical trials have demonstrated that the use of diuretics is associated with poor outcomes in patients with CHF [40][41][42] . The present study also showed that the use of furosemide is significantly and independently related to poor outcomes in CHF patients.…”

Section: Effects Of Medication On the Outcomes Of Chf Patientsmentioning

confidence: 99%

Effects of Eicosapentaenoic Acid on the Levels of Inflammatory Markers, Cardiac Function and Long-Term Prognosis in Chronic Heart Failure Patients with Dyslipidemia

Kohashi

Nakagomi

Saiki

et al. 2014

JAT

View full text Add to dashboard Cite

Aims:The effects of eicosapentaenoic acid (EPA) on the levels of inflammatory markers, cardiac function and long-term prognosis in chronic heart failure (CHF) patients with dyslipidemia remain unclear. Methods: A total of 139 CHF patients with a mean left ventricular ejection fraction (LVEF) of 37.6± 8.0% were divided into two groups based on whether EPA was included in their treatment regimen: the EPA group (n = 71) and the no EPA group (n = 68). Only patients with dyslipidemia at baseline (entry) were treated with EPA. The monocyte chemoattractant protein (MCP)-1 and asymmetric dimethylarginine (ADMA) levels were measured at baseline and after 12 months of treatment. Results: At 12 months, in the EPA group, the LVEF had improved and the MCP-1 and ADMA levels had decreased (respectively, p＜0.001); however, in the no EPA group, the LVEF had worsened, while the MCP-1 and ADMA levels had increased (respectively, p＜0.001).

show abstract

Characteristics, management, and outcomes for patients during hospitalization due to worsening heart failure—A report from the Japanese Cardiac Registry of Heart Failure in Cardiology (JCARE-CARD)

Cited by 63 publications

References 33 publications

Clinical Significance of Get With the Guidelines–Heart Failure Risk Score in Patients With Chronic Heart Failure After Hospitalization

Clinical Significance of Get With the Guidelines–Heart Failure Risk Score in Patients With Chronic Heart Failure After Hospitalization

Clinical Characteristics of Adult Patients With Congenital Heart Disease Hospitalized for Acute Heart Failure

Effects of Eicosapentaenoic Acid on the Levels of Inflammatory Markers, Cardiac Function and Long-Term Prognosis in Chronic Heart Failure Patients with Dyslipidemia

Contact Info

Product

Resources

About